• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Glucagon-like peptide-1 receptor agonists associated with lower depression risk in older adults with diabetes

byAdrian WongandThomas Su
February 24, 2025
in Endocrinology, Pharma, Psychiatry
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of depression compared with dipeptidyl peptidase-4 inhibitors among older patients with type 2 diabetes.

2. GLP-1RAs were associated with a similar reduction in risk of depression compared with sodium-glucose cotransporter-2 inhibitors.

Evidence Rating Level: 2 (Good)

Study Rundown: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been associated with various effects in treating type 2 diabetes (T2D), including cardiorenal benefits and weight loss. They are known to cross the blood-brain barrier and exert central dopaminergic effects, which raises concerns that they may also give rise to psychological harms such as depression and suicidality. Although pre-clinical studies suggest that GLP-1RAs may have antidepressant effects, population-based studies have shown mixed results. This study aimed to determine the risk of depression in older adults with diabetes on GLP-1RAs compared with sodium-glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is). It was found that GLP-1RAs were not associated with a significant change in risk of depression compared with SGLT2is. However, GLP-1RAs were associated with a one-tenth reduction in depression risk compared with DPP4is. Notably, subgroup analyses showed that the risk of incident depression among patients on GLP-1RAs decreased with longer treatment duration compared with both SGLT2is and DPP4is. The generalizability of this study was limited by its broad patient inclusion criteria; the possibility of unmeasured confounding; the relatively short median follow-up; and its focus on older adults. Nevertheless, this study suggested that GLP-1RAs could have antidepressant effects, particularly with longer treatment durations, thus making them a potential tool for treating diabetes in those at risk for depression.

Click to read the study in AIM

Relevant Reading: Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review

RELATED REPORTS

Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

In-Depth [retrospective cohort]: This target trial emulation investigated the risk for depression among older patients initiating GLP-1RA treatment compared with SGLT2is and DPP4is. Inclusion criteria were patients aged 66 years or older newly beginning treament with GLP-1RAs, SGLT2is, or DPP4is. Exclusion criteria included diagnosis of type 1 diabetes; end-stage renal disease or dialysis; preexisting depression or other mood disorders; use of antidepressants within 1 year prior to treatment initiation; and concomitant use of GLP-1RAs and control medications. After propensity score matching, risk for incident depression over time was calculated using Kaplan-Meier plots. A total of 14,665 pairs of patients were generated for comparing GLP-1RAs with SGLT2is, and 13,711 pairs were generated for comparing GLP-1RAs with DPP4is. In the GLP-1RA versus SGLT2i cohort, 961 GLP-1RA users and 902 SGLT2i users developed depression, yielding incidence rates of 49.02 and 45.54 per 1000 person-years for GLP-1RA and SGLT2i, respectively (rate difference, 3.48 per 1000 person-years [95% CI, -0.81 to 7.78]; hazard ratio [HR], 1.07 [95% CI, 0.98 to 1.18]). In the GLP-1RA versus DPP4i cohort, 963 GLP-1RA users and 1075 SGLT2i users developed depression, yielding incidence rates of 51.39 and 57.17 per 1000 person-years for GLP-1RA and SGLT2i, respectively (rate difference, -5.78 per 1000 person-years [95% CI, -10.49 to -1.07]; HR, 0.90 [95% CI, 0.82 to 0.98]). Within the subgroup analyses, patients on GLP-1RAs with longer treatment durations were associated with lower incident depression risk compared with both SGLT2is (HR for <0.5 years, 1.18 [95% CI, 1.04 to 1.33]; HR for ≥1 year, 0.84 [95% CI, 0.71 to 1.00]) and DPP4is (HR for <0.5 years, 1.08 [95% CI, 0.96 to 1.22]; HR for ≥1 year, 0.70 [95% CI, 0.59 to 0.82]). Overall, this study suggested that GLP1-RAs may have a similar effect on depression risk compared with SGLT2is, with a potential increase in effectiveness with longer treatment durations.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: depressiondiabetes mellitusglucagon-like peptide-1 (GLP-1) receptor agonistsobesityolder adultsType 2 Diabetes Mellitus
Previous Post

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

Next Post

Levothyroxine supplementation in pregnancy not linked to prematurity risk

RelatedReports

Majority of obese tenth-graders already obese by fifth grade
Chronic Disease

Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss

June 23, 2025
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Neurology

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

June 20, 2025
Next Post
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Levothyroxine supplementation in pregnancy not linked to prematurity risk

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

Strict tobacco licensing laws linked to reduced adolescent smoking initiation

Characterization of increased cryptogenic ischemic stroke risk from smoking

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.